<DOC>
	<DOCNO>NCT02101164</DOCNO>
	<brief_summary>This study estimate total time preparation administration denosumab total time preparation administration pamidronate .</brief_summary>
	<brief_title>Evaluate Time Associated With Preparation &amp; Administration Denosumab/Pamidronate Patients With Solid Tumors Metastatic Bone Disease</brief_title>
	<detailed_description />
	<mesh_term>Bone Diseases</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<criteria>Diagnosis metastatic bone disease secondary solid tumor ( eg , breast cancer , lung cancer , etc ) . An Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Subject one following : consider pamidronate IV infusion denosumab SC injection treatment metastatic bone disease ( prescribe per Canadian product monograph ) ; OR schedule receive pamidronate IV infusion denosumab SC injection treatment metastatic bone disease ( prescribe per Canadian product monograph ) ; OR currently receive pamidronate IV infusion denosumab SC injection treatment metastatic bone disease AND receive 4 prior administration either product combine ( prescribe per Canadian product monograph ) . Subject serum calcium albuminadjusted serum calcium ≥ 2.0 mmol/L ( 8.0 mg/dL ) ≤ 2.9 mmol/L ( 11.5 mg/dL ) Diagnosis metastatic bone disease secondary multiple myeloma prostate cancer . Severe renal impairment ( creatinine clearance &lt; 30 mL/min ) Subject consider ambulatory pamidronate administration use infuser device ( ie , `` baby bottle '' ) . A known active infection Hepatitis B virus Hepatitis C virus . Subject know positive result human immunodeficiency virus ( HIV ) .Subject history malignancy within past 5 year , : Malignancy treat curative intent know active disease present ≥ 5 year enrollment felt low risk recurrence treat physician Adequately treated nonmelanoma skin cancer lentigo maligna without evidence disease Adequately treat cervical carcinoma situ without evidence disease Adequately treat breast ductal carcinoma situ without evidence disease Prostatic intraepithelial neoplasia without evidence prostate cancer Adequately treat urothelial papillary noninvasive carcinoma carcinoma situ . Subject history current evidence osteonecrosis/osteomyelitis jaw , active dental jaw condition require oral surgery , nonhealed dental/oral surgery , plan invasive dental procedure course study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>